Effect of Tofogliflozin on Cardiac Function: Potential Link Between Ketone Bodies and the Heart

Abstract

This report describes the effect of tofogliflozin, a sodium-glucose cotransporter 2 inhibitor (SGLT2i), on cardiac function and its related parameters including ketone bodies (acetoacetate and beta-hydroxybutyrate). One case received and two cases discontinued tofogliflozin. Changes of cardiometabolic parameters were compared at 3 months. A 65-year-old patient with decreased heart function received tofogliflozin 20 mg/day. Left ventricular ejection fraction (EF), functional shortening (%FS), or acetoacetate/beta-hydroxybutyrate levels were increased. A 68-year-old patient with normal heart function discontinued tofogliflozin 20 mg/day. EF, %FS or acetoacetate/beta-hydroxybutyrate levels were decreased. A 60-year-old patient with slightly decreased heart function discontinued tofogliflozin. No changes of EF, %FS, or acetoacetate/beta-hydroxybutyrate levels were noted. Taken together, these results suggest that ketone bodies and the heart function appear to be related (concomitant changes by tofogliflozin) and that tofogliflozin might have effects on cardiac function through modulating ketone bodies.




J Endocrinol Metab. 2017;7(3):94-97
doi: https://doi.org/10.14740/jem396e